

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 17-18	Q3 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Formulations Business - Key Markets	26,969	18,634	44.7%	72,094	56,724	27.1%
US Formulations	15,838	8,869	78.6%	41,924	27,240	53.9%
India Formulations	9,168	7,968	15.1%	24,486	24,039	1.9%
Latin America Formulations	758	659	15.1%	1,942	1,842	5.4%
Emerging Markets Formulations	1,206	1,138	6.0%	3,742	3,603	3.9%
Other Businesses and Alliances	4,949	4,390	12.7%	13,045	12,791	2.0%
Europe Formulations	649	654	-0.8%	1,801	2,003	-10.1%
Consumer Wellness	1,291	1,113	16.0%	3,636	3,393	7.1%
Animal Health & Others	1,342	1,134	18.3%	3,675	3,456	6.3%
APIs	1,137	1,053	8.0%	2,756	2,861	-3.7%
Alliances	530	435	21.8%	1,177	1,077	9.3%
Grand Total	31,918	23,024	38.6%	85,139	69,515	22.5%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 17-18	Q3 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Other Operating Income	679	614	10.5%	2,085	1,489	40.0%
Export Incentive	352	178	97.8%	1,023	645	58.6%
Royalty Income	3	16	-81.8%	9	66	-87.1%
Net Gain on foreign currency transactions and translation (Refer Note below)	-86	107	-180.6%		193	-100.0%
Others	409	313	30.8%	1,054	585	80.1%

Note : There was a net loss of Rs. 204 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and a net loss of Rs. 29 Mio. included in other operating expenses in Q3 17-18. Thus, on aggregate level, there was a loss of Rs. 319 Mio. on operating transactions (above EBIDTA line) in Q3 17-18 vs gain of Rs. 203 Mio. in Q3 16-17. See details below for more clarity.

Rs. Mio.	Q3 17-18	Q3 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Other Income	411	166	147.5%	846	555	52.5%
Interest & Dividend income	125	114	9.6%	329	416	-20.9%
Profit on sale of investments	40	20	94.7%	72	72	-0.2%
Others	246	31	685.5%	445	67	564.3%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 17-18	Q3 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
A. On operating transactions (above EBIDTA line)	319	-203	257.1%	91	-407	122.4%
a. Included in other operating income	86	-106	181.1%		-193	100.0%
b. Included in cost of goods	204	-97	310.3%	62	-214	129.0%
c. Included in other expenses	29			29		
B. On other income (pertaining to foreign currency borrowings)	-153			-153		
C. On Foreign Currency Borrowings (part of interest cost)	-124	-63	-96.8%	-38	-26	-46.2%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	42	-266	115.8%	-100	-433	76.9%

Details of R&D Expenses

Rs. Mio.	Q3 17-18	Q3 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
Total R&D Expenses	2,071	2,210	-6.3%	6,866	5,359	28.1%

Consolidated Capex for Apr-Dec 17

**Rs. 6984
Mio.**

R&D capex included in above for Apr-Dec 17

**Rs. 282
Mio.**